Stay updated on Pembrolizumab Plus Olaparib vs Abiraterone in mCRPC Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab Plus Olaparib vs Abiraterone in mCRPC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab Plus Olaparib vs Abiraterone in mCRPC Clinical Trial page

  1. Check
    4 days ago
    Change Detected
    Summary
    The footer revision changes from v3.7.2 to v3.8.0; the page continues to show a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-11-01T15:42:48.000Z thumbnail image
  2. Check
    11 days ago
    Change Detected
    Summary
    A banner announces NIH’s transition from using “Artificial Intelligence” to “Super Intelligence” terminology. It appears above the unavailable study record.
    Difference
    1%
    Check dated 2026-10-25T15:47:56.000Z thumbnail image
  3. Check
    18 days ago
    Change Detected
    Summary
    The footer now displays site revision v3.7.2 instead of v3.7.1.
    Difference
    0.2%
    Check dated 2026-10-18T16:32:18.000Z thumbnail image
  4. Check
    25 days ago
    Change Detected
    Summary
    The page now shows a 403 Forbidden message in the study-record area, and the footer revision changes from v3.7.0 to v3.7.1.
    Difference
    0.2%
    Check dated 2026-10-11T16:40:23.000Z thumbnail image
  5. Check
    46 days ago
    Change Detected
    Summary
    The page now displays a 403 Forbidden error, replacing the study content with a standard error view and leaving the site chrome intact.
    Difference
    19%
    Check dated 2026-09-20T22:34:19.000Z thumbnail image
  6. Check
    67 days ago
    Change Detected
    Summary
    The page adds a 2018 NIH grant/contract funding note and updates the page revision to v3.6.6, removing the previous v3.6.5 reference.
    Difference
    0.0%
    Check dated 2026-08-30T21:57:41.000Z thumbnail image

Stay in the know with updates to Pembrolizumab Plus Olaparib vs Abiraterone in mCRPC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Plus Olaparib vs Abiraterone in mCRPC Clinical Trial page.